CoChat

Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/ PD ‐1 blockade therapy

Open access
Zuazo, Miren, Arasanz, Hugo, Fernández‐Hinojal, Gonzalo, García‐Granda, Maria Jesus, Gato, María, Bocanegra, Ana, Martínez, Maite, Hernández, Berta, Teijeira, Lucía, Morilla, Idoia, Lecumberri, Maria Jose, Fernández de Lascoiti, Angela, Vera, Ruth, Kochan, Grazyna, Escors, David · 2019 · EMBO Molecular Medicine
Cited by 198

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

The majority of lung cancer patients progressing from conventional therapies are refractory to PD-L1/PD-1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients with functional systemic CD4 T cells included all objective responders and could be identified before the start of therapy by having a high proportion of memory CD4 T cells. In these patients, CD4 T cells possessed significant proliferative capacities, low co-expression of PD-1/LAG-3 and were responsive to PD-1 blockade ex vivo and in vivo. In contrast, patients with dysfunctional systemic CD4 immunity did not respond even though they had lung cancer-specific T cells. Although proficient in cytokine production, CD4 T cells in these patients proliferated very poorly, strongly co-upregulated PD-1/LAG-3, and were largely refractory to PD-1 monoblockade. CD8 immunity only recovered in patients with functional CD4 immunity. T-cell proliferative dysfunctionality could be reverted by PD-1/LAG-3 co-blockade. Patients with functional CD4 immunity and PD-L1 tumor positivity exhibited response rates of 70%, highlighting the contribution of CD4 immunity for efficacious PD-L1/PD-1 blockade therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201910293

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 198

Metadata

Authors
Zuazo, M., Arasanz, H., Fernández‐Hinojal, G., García‐Granda, M. J., Gato, M., Bocanegra, A., Martínez, M., Hernández, B., Teijeira, L., Morilla, I., Lecumberri, M. J., Fernández de Lascoiti, A., Vera, R., Kochan, G., & Escors, D.
Venue
EMBO Molecular Medicine
Published
2019-06-06
Volume
11
Issue
7
Pages
e10293-e10293
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2951492084
Cited by
198
References
19
FWCI
11.70
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/ PD ‐1 blockade therapy. https://app.cochat.ai/papers/10.15252/emmm.201910293
The paper
Zuazo, M., Arasanz, H., Fernández‐Hinojal, G., García‐Granda, M. J., Gato, M., Bocanegra, A., Martínez, M., Hernández, B., Teijeira, L., Morilla, I., Lecumberri, M. J., Fernández de Lascoiti, A., Vera, R., Kochan, G., & Escors, D. (2019). Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/ PD ‐1 blockade therapy. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201910293

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.